A new dextran-graft-polybutylmethacrylate copolymer coated on 316L metallic stents enhances endothelial cell coverage

Preparation and characterization of polydopamine and n-butyl methacrylate copolymer coatings on titanium-nickel alloy stents

Cardiovascular diseases pose a significant global health threat, and stents play a crucial role in managing these diseases. However, challenges exist with respect to the poor adhesion of stent coatings. Cardiac stents are often composed of titanium-nickel (TiNi) alloys as the metallic component and poly(n-butyl methacrylate) (PBMA) as the coating. The poor adhesion of PBMA to TiNi alloy surface may cause detachment and subsequent thrombosis post-implantation. This study utilizes Reversible Addition-Fragmentation Chain Transfer (RAFT) polymerization to synthesize a novel block copolymer, PBMA-b-PVP, composed of PBMA and poly(N-vinylpyrrolidone) (PVP). TiNi alloy surfaces are functionalized with polydopamine (PDA) to enhance polymer coating adhesion. PBMA-b-PVP exhibits a remarkable improvement in adhesion from class 5 to class 0 and high coating stability after a 15 days immersion in a phosphate buffer solution. The corrosion current density is reduced by 44% with the incorporation of PDA into PBMA-b-PVP coatings, suggesting high corrosion resistance. PDA-functionalized coatings promote cell viability without cytotoxicity, suggesting high biocompatibility. This study provides a robust strategy for preparing stent coatings with high adhesion, corrosion resistance, and biocompatibility.

Optical spectroscopy study of the interaction between curcumin and acrylic polymers

This paper presents the results of a study conducted on the interaction between curcumin, a compound with several biomedical applications in traditional and modern medicine, and the acrylic polymers poly(methyl methacrylate), poly(ethyl methacrylate), and poly(n-butyl methacrylate), through photophysical experiments in curcumin/acrylic polymers casting films. Optical absorption intensity at ~340 nm increases relatively to its maximum at ~417 nm when the amount of curcumin in the polymeric film decreases, due to a significant change in the concentration of the isomers cis- or trans-form of curcumin, regardless of the acrylic polymer. Fluorescence (FL) spectra of the films depend on the curcumin concentration in the matrix with well-resolved line shape. They show two distinct bands, one at ~525 nm, for higher curcumin concentration (5.00 mmol.L^-1), related to the aggregated curcumin species, and another at ~465 nm, for lower concentration of curcumin (0.10 mmol.L^-1), related to the effects of the solvent on the conformational structure of the curcumin molecule and the presence of the trans-form of curcumin. The parameter K_agg, related to the contribution of the aggregated curcumin, shows the influence of the polymeric lateral chain length of the matrix in the de-aggregation of the curcumin. The Huang-Rhys factor indicates that curcumin aggregated species are conformationally more stable, and that the isolate species depends on the chemical environment and the matrix/curcumin interaction, decreasing its conformational degrees of freedom. Arrhenius plots, obtained via FL experiment in function of the sample temperature, show that, for higher curcumin concentration, the value for the relaxation energy process is not well defined, due the decrease in the interaction between the matrix and the curcumin molecules. With these results, it is possible to infer that the interaction matrix/curcumin must occur via lateral chemical alkyl groups.

Astaxanthin Complexes to Attenuate Muscle Damage after In Vivo Femoral Ischemia-Reperfusion

(1) Background: Reperfusion injury refers to the cell and tissue damage induced, when blood flow is restored after an ischemic period. While reperfusion reestablishes oxygen supply, it generates a high concentration of radicals, resulting in tissue dysfunction and damage. Here, we aimed to challenge and achieve the potential of a delivery system based on astaxanthin, a natural antioxidant, in attenuating the muscle damage in an animal model of femoral hind-limb ischemia and reperfusion. (2) Methods: The antioxidant capacity and non-toxicity of astaxanthin was validated before and after loading into a polysaccharide scaffold. The capacity of astaxanthin to compensate stress damages was also studied after ischemia induced by femoral artery clamping and followed by varied periods of reperfusion. (3) Results: Histological evaluation showed a positive labeling for CD68 and CD163 macrophage markers, indicating a remodeling process. In addition, higher levels of Nrf2 and NQO1 expression in the sham group compared to the antioxidant group could reflect a reduction of the oxidative damage after 15 days of reperfusion. Furthermore, non-significant differences were observed in non-heme iron deposition in both groups, reflecting a cell population susceptible to free radical damage. (4) Conclusions: Our results suggest that the in situ release of an antioxidant molecule could be effective in improving the antioxidant defenses of ischemia/reperfusion (I/R)-damaged muscles.

In vitro and in vivo evaluation of a dextran-graft-polybutylmethacrylate copolymer coated on CoCr metallic stent

Introduction: The major complications of stent implantation are restenosis and late stent thrombosis. PBMA polymers are used for stent coating because of their mechanical properties. We previously synthesized and characterized Dextrangraft-polybutylmethacrylate copolymer (Dex-PBMA) as a potential stent coating. In this study, we evaluated the haemocompatibility and biocompatibility properties of Dex-PBMA in vitro and in vivo. Methods: Here, we investigated: (1) the effectiveness of polymer coating under physiological conditions and its ability to release Tacrolimus®, (2) the capacity of Dex-PBMA to inhibit Staphylococcus aureus adhesion, (3) the thrombin generation and the human platelet adhesion in static and dynamic conditions, (4) the biocompatibility properties in vitro on human endothelial colony forming cells ( ECFC) and on mesenchymal stem cells (MSC) and in vivo in rat models, and (5) we implanted Dex-PBMA and Dex-PBMA_TAC coated stents in neointimal hyperplasia restenosis rabbit model. Results: Dex-PBMA coating efficiently prevented bacterial adhesion and release Tacrolimus®. Dex-PBMA exhibit haemocompatibility properties under flow and ECFC and MSC compatibility. In vivo, no pathological foreign body reaction was observed neither after intramuscular nor intravascular aortic implantation. After Dex-PBMA and Dex-PBMA_TAC coated stents 30 days implantation in a restenosis rabbit model, an endothelial cell coverage was observed and the lumen patency was preserved. Conclusion: Based on our findings, Dex-PBMA exhibited vascular compatibility and can potentially be used as a coating for metallic coronary stents.